Quantum Small Cap Fund
The Scheme seeks to generate capital appreciation by investing predominantly in Small Cap Stocks. There is no assurance that the investment objective of the scheme will be achieved.
Growthvine rating: 2/5 — ranked #26 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹13.21 (as of 2026-10-01) |
|---|
| AUM | ₹265 Cr |
|---|
| Expense ratio | 1.84% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Chirag Mehta |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 180 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −18.76% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 73.5% of NIFTY Smallcap 250's upside and 67.9% of its downside.
Market cap allocation
| Large cap | 6.2% |
|---|
| Mid cap | 4.2% |
|---|
| Small cap | 89.6% |
|---|
Concentration
| Top 5 holdings | 14.1% |
|---|
| Top 10 holdings | 26.5% |
|---|
| Total holdings | 58 |
|---|
| Index overlap | 9.5% |
|---|
| Active share | 90.5% |
|---|
Top holdings
- TREPS — 7.9%
- Supriya Lifescience Limited — 3.3%
- Karur Vysya Bank Ltd. — 2.9%
- Uniparts India Limited — 2.7%
- Engineers India Ltd. — 2.7%
- ALIVUS LIFE SCIENCES LIMITED — 2.6%
- Lumax Auto Technologies Ltd. — 2.5%
- Star Health and Allied Insurance Company Limited — 2.5%
- CCL Products (India) Ltd. — 2.5%
- Lumax Industries Ltd. — 2.5%
Top sectors
- Banking & Financial — 15.7%
- Automobile — 14.1%
- Pharma & Biotech — 9.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.8% | Q4 (Bottom) | #28 of 34 |
| 2025 | 3.9% | Q1 (Top) | #1 of 30 |
| 2024 | 15.4% | Q4 (Bottom) | #28 of 28 |